The prevalence of DME was estimated to be 2.8 million people in the US, EU5 and
The Company is progressing its pipeline of innovative clinical drug candidates for treating DME.
THR-687 is a potential best in class small molecule pan-RGD integrin antagonist being developed to treat DME with the possibility to become the standard of care for all treatment-naive DME patients.
We have recently started our Phase 2 study of THR-149 in patients with DME. This two-part study will first select the optimal dosing regimen of THR-149 and will then compare this in a multiple dosing regimen with aflibercept in terms of the improvements in best corrected visual acuity that it can deliver. This Phase 2 data is designed to support our plans to position THR-149 as the treatment of choice for the large number of DME patients who have a sub-optimal response to anti-VEGF therapy.
In January we announced positive and highly promising Phase 1 results with THR-687 which further strengthened our confidence that this novel pan-RGD integrin antagonist could deliver improved visual outcomes to a broad population of DME patients when compared to anti-VEGFs, the current standard of care. We are currently carrying out additional multiple dose preclinical studies to support an IND (Investigation New Drug Application) as part of our plan to start a Phase 2 study in mid-2021.
I am also pleased to welcome to our senior management team
We believe we are well positioned to build the industry's leading DME franchise, based on successfully developing THR-149 and THR-687, two novel and complimentary drug candidates that could offer improved therapeutic options beyond anti-VGEFs. We are convinced that this focused strategy will deliver significant benefits to DME patients globally as well as value to our shareholders.'
Contact:
Tel: +32 16 75 13 10
Email: wouter.piepers@oxurion.com
About
The Company is currently conducting a Phase 2 clinical trial evaluating multiple injections of THR-149 with DME-patients who previously responded sub-optimally to anti-VEGF therapy. THR-149 was developed in conjunction with
THR-687 is a pan-RGD integrin inhibitor, that is initially being developed as a potential new standard of care for all DME patients.
Positive topline results in a Phase 1 clinical study assessing THR-687 as a treatment for DME were announced in
THR-687 is an optimized compound derived from a broader library of integrin inhibitors in-licensed from
Important information about forward-looking statements
Certain statements in this press release may be considered 'forward-looking'. Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume an obligation to update or revise any forward-looking statement, whether as a result of new information, future events or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forward-looking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of
(C) 2020 Electronic News Publishing, source